Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie to acquire Apogee Therapeutics for $10.9 billion in cash

Neutral Impact 4 of 5 m&a Written later

AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, a total equity value of about $10.9 billion, according to a June 22, 2026 joint press release. The deal is expected to close in the third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals, and AbbVie expects it to be accretive to adjusted diluted earnings per share beginning in 2032.

Key points

  • Price: $135.11 per Apogee share in cash; total equity value of about $10.9 billion
  • Expected closing: third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals
  • Accretion to AbbVie adjusted diluted EPS expected beginning in 2032
  • Fairmount Funds Management LLC and Venrock Associates have signed voting agreements supporting the deal

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECJun 22, 2026, 7:11 AM ET
Accession number0001104659-26-076067

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.